PhysIOL SA and Carl Zeiss Meditec AG settle
legal dispute
Liège, 18.08.2014.
PhysIOL SA and Carl Zeiss Meditec AG have settled their legal dispute about patents
and utility models for trifocal intraocular lenses (IOL) out of court. Under a
settlement agreement, the two parties have agreed to permit the unrestricted
distribution of products from the FINEVISION line (PhysIOL SA) and AT LISA tri line
(Carl Zeiss Meditec AG) as well as products based on this technology. Contrary to a
statement made in an earlier press release by PhysIOL SA in the course of the
proceedings, PhysIOL SA recognized IP rights held by Carl Zeiss Meditec AG and
therefore accepted entering into an agreement with Carl Zeiss Meditec AG. Carl Zeiss
Meditec AG does not make any payments to PhysIOL SA under the agreement. The
information comes from both companies.
The agreement extends not only to markets protected directly by industrial property
rights such as Germany, the USA and Japan, but also to regions that will be covered
by future rights. The agreement applies with immediate effect. Both companies have
undertaken to withdraw all infringement suits, patent opposition proceedings and a
cancellation request for a utility model. The specific terms of the settlement are
confidential.
Intraocular lenses (IOL) are used primarily in the treatment of cataract. The
development of innovative new lenses has significantly improved opportunities for
treatment over the past few years. Trifocal intraocular lenses allow suitable patients
PhysIOL SA and Carl Zeiss Meditec AG settle
legal dispute
Liège, 18.08.2014.
PhysIOL SA and Carl Zeiss Meditec AG have settled their legal dispute about patents
and utility models for trifocal intraocular lenses (IOL) out of court. Under a
settlement agreement, the two parties have agreed to permit the unrestricted
distribution of products from the FINEVISION line (PhysIOL SA) and AT LISA tri line
(Carl Zeiss Meditec AG) as well as products based on this technology. Contrary to a
statement made in an earlier press release by PhysIOL SA in the course of the
proceedings, PhysIOL SA recognized IP rights held by Carl Zeiss Meditec AG and
therefore accepted entering into an agreement with Carl Zeiss Meditec AG. Carl Zeiss
Meditec AG does not make any payments to PhysIOL SA under the agreement. The
information comes from both companies.
The agreement extends not only to markets protected directly by industrial property
rights such as Germany, the USA and Japan, but also to regions that will be covered
by future rights. The agreement applies with immediate effect. Both companies have
undertaken to withdraw all infringement suits, patent opposition proceedings and a
cancellation request for a utility model. The specific terms of the settlement are
confidential.
Intraocular lenses (IOL) are used primarily in the treatment of cataract. The
development of innovative new lenses has significantly improved opportunities for
treatment over the past few years. Trifocal intraocular lenses allow suitable patients
การแปล กรุณารอสักครู่..